Discover the hidden triggers of idiopathic pulmonary fibrosis (IPF) in your home. Learn to minimize risks from scents, cleaning products, allergens, GERD, and infections.

-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...

BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of ...

A hybrid model combining LM, GA, and BP neural networks improves TCM's diagnostic accuracy for IPF, achieving 81.22% ...

Please provide your email address to receive an email when new articles are posted on . Saracatinib appeared to be “equal or superior” in stopping fibrotic responses compared with two FDA-approved ...

Project Leader: Steven Duncan, M.D. Idiopathic pulmonary fibrosis (IPF) is a morbid fibroproliferative lung disease of older adults that causes progressive dyspnea and hypoxemia. Current treatments ...

INGELHEIM, Germany--(BUSINESS WIRE)--New results from a global survey supported by Boehringer Ingelheim 1 reveal the emotional and practical challenges facing people with idiopathic pulmonary fibrosis ...

Please provide your email address to receive an email when new articles are posted on . Researchers found differences between the two settings when evaluating the number of patients who agreed with ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...